215 related articles for article (PubMed ID: 35627262)
21. High Expression of RRM1 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.
Mao G; Shan C; Li W; Liang B; Ma L; Zhang S
Int J Gen Med; 2022; 15():2607-2620. PubMed ID: 35282644
[TBL] [Abstract][Full Text] [Related]
22. Genome-Wide Analysis of Prognostic lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma.
Lin P; Wen DY; Li Q; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 48(5):1953-1967. PubMed ID: 30092571
[TBL] [Abstract][Full Text] [Related]
23. Small regulatory polypeptide of amino acid response negatively relates to poor prognosis and controls hepatocellular carcinoma progression via regulating microRNA-5581-3p/human cardiolipin synthase 1.
Yin J; Liu Q; Chen C; Liu W
J Cell Physiol; 2019 Aug; 234(10):17589-17599. PubMed ID: 30825207
[TBL] [Abstract][Full Text] [Related]
24. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
Huang B; Huang M; Li Q
Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
[TBL] [Abstract][Full Text] [Related]
25. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
Yang F; Lv LZ; Cai QC; Jiang Y
World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma.
He Y; Meng XM; Huang C; Wu BM; Zhang L; Lv XW; Li J
Cancer Lett; 2014 Mar; 344(1):20-27. PubMed ID: 24183851
[TBL] [Abstract][Full Text] [Related]
27. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
28. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
29. LINC01419 facilitates hepatocellular carcinoma growth and metastasis through targeting EZH2-regulated RECK.
Zhang G; Chen X; Ma L; Ding R; Zhao L; Ma F; Deng X
Aging (Albany NY); 2020 Jun; 12(11):11071-11084. PubMed ID: 32522890
[TBL] [Abstract][Full Text] [Related]
30. LINC00638/hsa-miR-29b-3p axis-mediated high expression of CDCA4 correlates with tumor immune infiltration and hepatocellular carcinoma progression.
Wang B; Chen L; Li Q; Zhou J; Jin W
Transl Cancer Res; 2023 May; 12(5):1290-1306. PubMed ID: 37304553
[TBL] [Abstract][Full Text] [Related]
31. Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression.
Chen L; Yao H; Wang K; Liu X
J Cell Biochem; 2017 Dec; 118(12):4836-4843. PubMed ID: 28543721
[TBL] [Abstract][Full Text] [Related]
32. Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy.
Bae AN; Jung SJ; Lee JH; Lee H; Park SG
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208478
[No Abstract] [Full Text] [Related]
33. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
34. LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.
Xu K; Zhang Z; Qian J; Wang S; Yin S; Xie H; Zhou L; Zheng S
Exp Cell Res; 2019 Jul; 380(2):198-204. PubMed ID: 31004581
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC.
Zeng B; Lin Z; Ye H; Cheng D; Zhang G; Zhou J; Huang Z; Wang M; Cai C; Zeng J; Tang C; Liu J
Cell Physiol Biochem; 2018; 46(3):1122-1133. PubMed ID: 29669339
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.
Zeng T; Luo L; Huang Y; Ye X; Lin J
Biomed Res Int; 2021; 2021():6665918. PubMed ID: 33748276
[TBL] [Abstract][Full Text] [Related]
37. LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression.
Xu X; Gu J; Ding X; Ge G; Zang X; Ji R; Shao M; Mao Z; Zhang Y; Zhang J; Mao F; Qian H; Xu W; Cai H; Wang F; Zhang X
Cell Death Dis; 2019 Oct; 10(10):752. PubMed ID: 31582742
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.
Hu S; Zhang J; Guo G; Zhang L; Dai J; Gao Y
PLoS One; 2022; 17(4):e0267117. PubMed ID: 35482720
[TBL] [Abstract][Full Text] [Related]
39. High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway.
Li X; Cheng T; He Y; Zhou S; Wang Y; Zhang K; Yu P
Life Sci; 2019 Sep; 232():116602. PubMed ID: 31251997
[TBL] [Abstract][Full Text] [Related]
40. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
